• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

血压控制的理论与实践之间的差异对社区有何影响?

What are the implications for the community of the discrepancy between the theory and practice of BP control?

作者信息

Jackson R

机构信息

Department of Community Health, School of Medicine, University of Auckland, New Zealand.

出版信息

J Hum Hypertens. 1995 Jul;9 Suppl 2:S25-8.

PMID:7562894
Abstract

Epidemiological data suggest that the lower the BP, the lower the cardiovascular risk. This is true across a broad range of BP levels, including those considered 'normal'; more than half of all cardiovascular events attributed to raised BP occur when DBP is < or = 95 mmHg. The belief that lowering BP too far is harmful is based on the hypothesis of a J-shaped relationship between BP and risk of cardiovascular disease. The weight of evidence now clearly suggests, however, that the J-shaped curve is not a consequence of treatment, but of underlying cardiovascular dysfunction that reduces BP and increases morbidity and mortality. Current prospective observational data give no evidence of a threshold BP below which there is no further reduction in cardiovascular disease risk. The average BP reductions in randomised trials are 5-6 mmHg (diastolic) and 10-12 mmHg (systolic), which would be expected to reduce the incidence of stroke by 35% and of coronary heart disease by 21%. If average BP reductions were doubled, prospective observational studies suggest the cardiovascular risk would be reduced by a further 15-20%.

摘要

流行病学数据表明,血压越低,心血管风险越低。在广泛的血压水平范围内都是如此,包括那些被认为“正常”的血压水平;舒张压小于或等于95 mmHg时,超过一半的心血管事件归因于血压升高。认为将血压降得过低有害这一观点是基于血压与心血管疾病风险之间呈J形关系的假设。然而,目前的证据明确表明,J形曲线不是治疗的结果,而是潜在的心血管功能障碍的结果,这种功能障碍会降低血压并增加发病率和死亡率。目前的前瞻性观察数据没有证据表明存在一个血压阈值,低于该阈值心血管疾病风险就不会进一步降低。随机试验中血压的平均降幅为舒张压5 - 6 mmHg和收缩压10 - 12 mmHg,预计这将使中风发病率降低百分之三十五,冠心病发病率降低百分之二十一。如果平均血压降幅翻倍,前瞻性观察研究表明心血管风险将进一步降低百分之十五至二十。

相似文献

1
What are the implications for the community of the discrepancy between the theory and practice of BP control?血压控制的理论与实践之间的差异对社区有何影响?
J Hum Hypertens. 1995 Jul;9 Suppl 2:S25-8.
2
The hidden truth: what do the clinical trials really tell us about BP control?
J Hum Hypertens. 1995 Jul;9 Suppl 2:S3-7.
3
[Target values in hypertension treatment. Will they apply in older patients with hypertension, diabetics and in patients with IHD?].[高血压治疗的目标值。它们是否适用于老年高血压患者、糖尿病患者和缺血性心脏病患者?]
Vnitr Lek. 2009 Sep;55(9):833-40.
4
Stroke and coronary heart disease in treated hypertension -- a prospective cohort study over three decades.经治疗的高血压患者中的中风和冠心病——一项长达三十年的前瞻性队列研究
J Intern Med. 2005 Jun;257(6):496-502. doi: 10.1111/j.1365-2796.2005.01497.x.
5
Elevated systolic blood pressure as a risk factor for cardiovascular and renal disease.收缩压升高作为心血管和肾脏疾病的一个危险因素。
J Hypertens Suppl. 1999 Jun;17(2):S7-13.
6
Actual blood pressure control: are we doing things right?实际的血压控制:我们做得对吗?
J Hypertens Suppl. 1998 Jan;16(1):S45-51.
7
[Cardiovascular risk stratification. Systolic, diastolic or pulse pressure?].[心血管风险分层。收缩压、舒张压还是脉压?]
Ital Heart J Suppl. 2001 Apr;2(4):356-8.
8
Impact of blood pressure control on cardiovascular events in 26,512 Japanese hypertensive patients: the Japan Hypertension Evaluation with Angiotensin II Antagonist Losartan Therapy (J-HEALTH) study, a prospective nationwide observational study.血压控制对26512名日本高血压患者心血管事件的影响:日本血管紧张素II拮抗剂氯沙坦治疗高血压评估(J-HEALTH)研究,一项全国性前瞻性观察研究。
Hypertens Res. 2008 Mar;31(3):469-78. doi: 10.1291/hypres.31.469.
9
[Calcium antagonists in cardiovascular disease. Clinical evidence from morbidity and mortality trials].[心血管疾病中的钙拮抗剂。发病率和死亡率试验的临床证据]
Drugs. 2000;59 Spec No 2:25-37.
10
On-treatment diastolic blood pressure and prognosis in systolic hypertension.收缩期高血压治疗期间的舒张压与预后
Arch Intern Med. 2007 Sep 24;167(17):1884-91. doi: 10.1001/archinte.167.17.1884.

引用本文的文献

1
Treated hypertensives with good medication compliance are still in a state of uncontrolled blood pressure in the Japanese elderly.在日本老年人群中,尽管治疗的高血压患者用药依从性良好,但仍有相当一部分患者的血压未得到有效控制。
Environ Health Prev Med. 2002 Nov;7(5):193-8. doi: 10.1007/BF02898004.
2
Compliance, quality of life, and cost effectiveness.依从性、生活质量和成本效益。
Curr Hypertens Rep. 1999 Dec;1(6):471-4. doi: 10.1007/s11906-996-0017-8.
3
Irbesartan: an updated review of its use in cardiovascular disorders.厄贝沙坦:关于其在心血管疾病中应用的最新综述。
Drugs. 2000 May;59(5):1187-206. doi: 10.2165/00003495-200059050-00014.
4
Felodipine/metoprolol: a review of the fixed dose controlled release formulation in the management of essential hypertension.非洛地平/美托洛尔:关于固定剂量控释制剂治疗原发性高血压的综述
Drugs. 2000 Jan;59(1):141-57. doi: 10.2165/00003495-200059010-00011.